OneOncology launches OneR, precision oncology research network October 19, 2020 -- OneOncology has formed a subsidiary named OneOncology Research Network (OneR) as a national nonexclusive clinical trial site management organization to enhance research programs underway at participating community oncology practices.
Endo to acquire BioSpecifics October 19, 2020 -- Endo will acquire all shares of BioSpecifics Technologies for $88.50 per share, or an estimated total of $540 million. As part of the acquisition, BioSpecifics will receive a royalty stream from Endo's collagenase-based therapies, including Xiaflex and Qwo, which were developed by BioSpecifics.
CHMP recommends approval for Janssen's mAb in psoriatic arthritis October 16, 2020 -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval for the expanded use of guselkumab (Tremfya), a monoclonal antibody (mAb) from the Janssen Pharmaceutical Companies of Johnson & Johnson.
CHMP recommends Alnylam's RNAi therapeutic for approval October 16, 2020 -- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) posted a positive opinion recommending approval for Alnylam Pharmaceutical's lumasiran, an investigational RNA interference (RNAi) therapeutic for the treatment of primary hyperoxaluria type 1.